ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f [g] h i j k l m n o p q r s t u v w x y z

Abstract Number: 1902

Gait Alterations Associated with Worsening Knee Pain over 2 Years: A Machine-learning Approach in the MultiCenter Osteoarthritis Study
Abstract Number: 1097

Gastrointestinal Malignancies in Sarcoidosis: A Nationwide Analysis
Abstract Number: 1799

Gender Based Differences in Clinical and Sonographic Assessment Among Patients with Psoriatic Arthritis
Abstract Number: 0406

Gender Differences in Clinical Features and Outcomes of Systemic Sclerosis: Analysis of Reuma.pt/SSc Registry
Abstract Number: 0592

Gender Modifies the Effect of Rheumatoid Arthritis on All-Cause Mortality
Abstract Number: 0351

Gene Signature Fingerprints Divide SLE Patients in Subgroups with Similar Biological Disease Profiles: A Multicenter Longitudinal Study
Abstract Number: 1551

Generation of Autoantibodies and Their Association with Rheumatic Disease Flares in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases and General Adult Population Following BNT162b2 mRNA Covid-19 Vaccination
Abstract Number: 1280

Generation of Evidence Supporting the Content Validity of SF-36, Lupus-Qol, and FACIT-Fatigue, and Newly Developed Patient-reported Outcome (PRO) Symptom Items to Address Conceptual Gaps for Use in Patient with Lupus Nephritis
Abstract Number: 1581

Genetic Effects on the Transition from Hyperuricemia to Gout
Abstract Number: 0884

Genetics of Longitudinal Disease Activity in Adults with Systemic Lupus Erythematosus
Abstract Number: 0776

Genetics of Neonatal Lupus Erythematosus Risk and Specific Manifestations
Abstract Number: 0522

Genetics of Rheumatoid Arthritis Remission; HLA-SE Associated with Remission in Anti-CCP Positive Patients
Abstract Number: 0521

Genome-Wide DNA Methylation and Gene Expression Signatures in Classical Monocytes from African Ancestry Patients with Systemic Sclerosis
Abstract Number: 1426

Genotype and Transfusion Dependence Predicts Mortality in VEXAS Syndrome, a Newly Described Disease with Overlap Inflammatory and Hematologic Features
Abstract Number: 0368

Geographical Prevalence of Family History in Patients with Axial SpA and Its Association with HLA-B27: Data from the Worldwide ASAS-perSpA Study
Abstract Number: 1403

Giant Cell Arteritis Subtypes: Data from the ARTESER Registry
Abstract Number: 0502

Global Transcriptomic Profiling Identifies Differential Gene Expression Signatures Between Inflammatory and Non-inflammatory Aortic Aneurysms
Abstract Number: 0694

Glucagon-like Peptide-1 Receptor Agonist Suppresses Muscle Fiber Necroptosis and Muscle Inflammation and Ameliorates Muscle Weakness in Experimental Polymyositis
Abstract Number: 1735

Glucocorticoid Discontinuation in Patients with Systemic Lupus Erythematosus with Prior Severe Organ Manifestation
Abstract Number: 1485

Glycosphingolipids: Potential Urine Biomarkers of Therapeutic Response in Lupus Nephritis
Abstract Number: 0742

Googling Rheumatic Diseases: Evaluating the Reliability of Information Found on the Internet
Abstract Number: 0682

Gout Management and Outcomes During the COVID-19 Pandemic in Late 2020-2021: A Cross-sectional Internet Survey
Abstract Number: 0680

Gout Stigma: Investigating the Existence of Gout Stigma and Its Impact on Patient Perceptions and Treatment Decisions
Abstract Number: 0968

Granzyme K+ CD8 T Cells Form the Core Population of Inflamed Human Tissue-associated CD8 T Cells
Abstract Number: 0173

Greater High-density Lipoprotein Levels over Time Are Linked to Lower Coronary Plaque Formation, Regression and Stabilization of High-risk Lesions in Rheumatoid Arthritis
Abstract Number: 1331

Guselkumab (TREMFYA®) Improves Anemia in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Randomized Controlled Clinical Trials
Abstract Number: 1329

Guselkumab (TREMFYA®) Maintains Resolution of Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Results Through 2 Years from a Phase 3 Study
Abstract Number: 1333

Guselkumab (TREMFYA®) Provides Consistent and Durable Pain Improvement in Patients with Active Psoriatic Arthritis: Results of 2 Phase 3, Randomized, Controlled Clinical Trials
Abstract Number: 1335

Guselkumab Provides Sustained Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis
Abstract Number: 1343

Guselkumab Treatment Modulates Core Psoriatic Arthritis Gene Expression in Two Phase 3 Clinical Trials (DISCOVER-1 and -2)
Abstract Number: 1808

Guselkumab-Treated Patients with Psoriatic Arthritis Achieved Clinically Meaningful Improvements in General Health Outcomes Measured with PROMIS-29 Through 52 Weeks: Results from the Phase 3 DISCOVER-1 Trial
Abstract Number: 0068

Gut Bacteria Causing Ankylosing Spondylitis Identified Through Mendelian Randomization Studies

Jump to: View All • a b c d e f [g] h i j k l m n o p q r s t u v w x y z